Scancell (LON:SCLP) Trading Up 4.1% – Still a Buy?

Shares of Scancell Holdings plc (LON:SCLP) traded up 4.1% during mid-day trading on Friday . The company traded as high as GBX 14 and last traded at GBX 13.01. 1,196,952 shares traded hands during mid-day trading, a decline of 43% from the average session volume of 2,108,023 shares. The stock had previously closed at GBX 12.50.

Scancell Stock Up 4.1%

The firm’s 50-day simple moving average is GBX 11.51 and its 200 day simple moving average is GBX 10.45. The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42. The company has a market cap of £135.05 million, a P/E ratio of -23.66 and a beta of 0.35.

Scancell (LON:SCLP) last announced its quarterly earnings data on Thursday, January 29th. The company reported GBX (0.55) EPS for the quarter. On average, research analysts forecast that Scancell Holdings plc will post -2.5361112 earnings per share for the current fiscal year.

About Scancell

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.